MannKind shares tumbled 18.18% to $1.08 in pre-market trading Tuesday after the company released disappointing Q1 results on Monday. The Valencia-based company reported a net loss of 6 cents per share, worse than the Wall Street projections of 4 cents a share in losses. MannKind’s portion of the loss-sharing under its licensing agreement with Sanofi stood at $5.5 million during March quarter.
MannKind’s cash reserves declining rapidly
The biopharmaceutical company’s cash and cash equivalents plunged from $59.1 million at the end of December to $27.7 million at the end of March. In February, the company received $250,000 in upfront fee from Receptor Life Sciences. Under its loan agreement with The Mann Group, MannKind can still borrow up to $30.1 million. Its stock has declined more than 65% in the last 12 months.
For much of the past decade, Crispin Odey has been waiting for inflation to rear its ugly head. The fund manager has been positioned to take advantage of rising prices in his flagship hedge fund, the Odey European Fund, and has been trying to warn his investors about the risks of inflation through his annual Read More
There were some positive signs as well. MannKind CEO Matthew Pfeffer said during the earnings call that 7 out of 10 patients are getting approved to take Afrezza through the prior authorization process. That could give Afrezza commercialization a much-needed boost because the inhaled insulin drug cannot take off without the support of insurers. Pfeffer added that the company will be hiring 60-70 salespeople in the next few months to talk to doctors and patients.
Pricing of direct public offering of common stock and warrants
Separately, the company also announced pricing of a direct public offering of up to 48.54 million shares of the common stock and warrants. Each common stock share will be sold with a warrant to buy 0.75 of a share of common stock (A warrants) and a warrant to buy 0.25 of a share of common stock (B warrants) for a price of $1.03. Investors can exercise the A warrants at a price of $1.50 apiece beginning upon issuance. The B warrants will be exercisable starting May 2017 at a price of $1.50 per share.
MannKind expects the offering to close on May 12, 2016, subject to customary closing conditions. The company said it was expecting about $50 million in gross proceeds from the offering. The net proceeds to MannKind are likely to be $47.5 million after taking out the placement agent’s fees. MannKind plans to use the net proceeds for general corporate purposes and working capital.